

Patient ID SAMPLE	Patient Name PATIENT, TEST	Birth Date 1974-08-04	Sex M	Age 50
Order Number SAMPLE	Client Order Number SAMPLE	Ordering Physician SAMPLE	Report Notes Sample Report	
Account Information SAMPLE		Collected 04 Aug 2024 14:39		

DHR Flow, B

Absolute Neutrophil Count

3589 cells/mcL

% PMA ox-DHR+

99.8 %

MFI PMA ox-DHR+

 6.73 MFI


% fMLP ox-DHR+

20.5 %

MFI fMLP ox-DHR+

 0.87 MFI


Control Absolute Neutrophil Count

2598 cells/mcL

Control % PMA x-DHR+

100.0 %

SDL

Reference Value
1700–7000

SDL

Reference Value
≥95

SDL

Reference Value
≥60

SDL

Reference Value
≥10

SDL

Reference Value
≥2

SDL

SDL

Reference Value
≥95

Control MFI PMA ox-DHR+

78.25 MFI

Control % fMLP ox-DHR+

65.7 %

Control MFI fMLP ox-DHR+

45.25 MFI

Interpretation

Shipping control received in lab.
Abnormal result.

ADDITIONAL INFORMATION

The assay involves measurement of NADPH oxidase activity in neutrophils (from sodium heparin blood) after stimulation with either PMA or fMLP. The relative proportion (%) of neutrophils for oxidative burst (DHR fluorescence) after PMA or fMLP stimulation is determined. Additionally, the mean fluorescence intensity (MFI) post-stimulation is determined.

A false-positive result for abnormal DHR fluorescence may be obtained in patients with complete myeloperoxidase deficiency, however, visual and quantitative assessment (MFI) of the DHR flow data can differentiate between CGD and MPO deficiency.

Received: 05 Aug 2024 14:34

Reported: 05 Aug 2024 14:39

SDL

Reference Value
≥60

SDL

Reference Value
≥10

SDL

Reference Value
≥2

1 SDL

Laboratory Notes

- 1 Analyte Specific Reagent: This test was developed and its performance characteristics determined by Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	Nikola Baumann Ph.D.	24D1040592